Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. (February 2017)

• Record Type: Journal Article
• Authors: Cash, Brooks D; Lacy, Brian E; Schoenfeld, Philip S; Dove, Leonard S; Covington, Paul S
• Is Part Of: American journal of gastroenterology. Volume 112:Number 2(2017)
• Publication Date: 2017-02
• Subjects: Stomach -- Diseases -- Periodicals; Intestines -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Gastrointestinal Diseases -- Periodicals; Electronic journals; Periodicals; 616.33
• DOI: 10.1038/ajg.2016.542
• Languages: English
• ISSNs: 0002-9270

Abstract

Abstract : Objectives: Eluxadoline is a mixed μ‐opioid receptor (OR) and κ‐OR agonist and δ‐OR antagonist, approved for the treatment of irritable bowel syndrome with diarrhea (IBS‐D). This analysis evaluated the safety and tolerability of eluxadoline 75 and 100 mg twice daily (BID) in one Phase 2 (IBS‐2001) and two Phase 3 (IBS‐3001 and IBS‐3002) studies. Methods: Adults with IBS‐D (Rome III criteria) were randomized to placebo or eluxadoline (75 or 100 mg) BID for 12 (IBS‐2001), 26 (IBS‐3002), or 52 (IBS‐3001) weeks. Safety data were pooled. Adverse events (AEs) were assessed, with special focus on opioid‐related AEs, including suspected sphincter of Oddi spasm (SOS) events. Results: 2, 776 patients were included in the enrolled set; the safety set comprised 2, 814 patients, based on actual treatments received. The most frequent AEs in the placebo and eluxadoline 75 and 100 mg groups were constipation (2.5, 7.4, and 8.1%, respectively) and nausea (5.0, 8.1, and 7.1%, respectively); discontinuation due to constipation was uncommon (0.3, 1.1, and 1.5%, respectively). Ten SOS events (10/1, 839; 0.5%) occurred in eluxadoline‐treated patients, manifesting as acute abdominal pain with elevated aminotransferases or lipase, or pancreatitis; all occurred in patients without a gallbladder. Eight of these events occurred with the higher dose of eluxadoline, within 1 week of initiation of therapy, and all resolved with eluxadoline discontinuation. There were five events independently adjudicated as pancreatitis not associated with SOS, three of which were associated with heavy alcohol use. Conclusions: Eluxadoline was well tolerated in Phase 2 and 3 trials, with constipation and nausea the most common AEs. Consistent with the known adverse effects of opioid agonists, clinically apparent SOS events were observed in eluxadoline‐treated patients. All occurred in patients without a gallbladder and the majority were observed in patients on the higher dose of eluxadoline, suggesting a possible association.